RT Journal Article
SR Electronic
T1 Sex-specific associations of adiposity with cardiometabolic traits: multi-life-stage cohort study with repeat metabolomics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.30.20240895
DO 10.1101/2020.11.30.20240895
A1 Linda M. O’Keeffe
A1 Joshua A. Bell
A1 Kate N. O’Neill
A1 Matthew Lee
A1 Mark Woodward
A1 Sanne Peters
A1 George Davey Smith
A1 Patricia M. Kearney
YR 2020
UL http://medrxiv.org/content/early/2020/12/02/2020.11.30.20240895.abstract
AB Background Sex differences in cardiometabolic disease risk are commonly observed across the life course but are poorly understood and may be due to different cardiometabolic consequences of adiposity in females and males. We examined whether adiposity influences cardiometabolic trait levels differently in females and males at four different life stages.Methods Data were from two generations (offspring, Generation 1 [G1] and their parents, Generation 0 [G0]) of the Avon Longitudinal Study of Parents and Children birth cohort study. Body mass index (BMI) and total fat mass from dual-energy x-ray absorptiometry were measured at mean age 9y, 15y and 18y in G1. Waist circumference was measured at 9y and 15y in G1. Concentrations of 148 cardiometabolic traits quantified using nuclear magnetic resonance spectroscopy were measured at 15y, 18y and 25y in G1. In G0, all three adiposity measures and the same 148 traits were available at 50y.Using linear regression models, sex-specific associations of adiposity measures at each time point (9y, 15y and 18y) with cardiometabolic traits 3 to 6 years later were examined in G1. In G0, sex-specific associations of adiposity measures and cardiometabolic traits were examined cross- sectionally at 50y.Results 3081 G1 and 4887 G0 participants contributed to analyses. BMI was more strongly associated with key atherogenic traits in males at younger ages (15y-25y) and associations were more similar between the sexes or stronger in females at 50y, particularly for apolipoprotein-B-containing lipoprotein particles and lipid concentrations. For example, a 1- SD (3.8 kg/m2) higher BMI at 18y was associated with 0.36 SD (95% Confidence Interval (CI) = 0.20, 0.52) higher concentrations of extremely large very-low-density lipoprotein (VLDL) particles at 25y in males compared with 0.15 SD (95% CI = 0.09, 0.21) in females. In contrast, at 50y, a 1-SD (4.8 kg/m2) higher BMI was associated with 0.33 SD (95% CI = 0.25, 0.42) and 0.30 SD (95% CI = 0.26, 0.33) higher concentrations of extremely large VLDL particles in males and females respectively. Sex-specific associations of DXA-measured fat mass and waist circumference were similar to findings for BMI in both generations and at all ages.Conclusion The results of this study suggest that the adverse cardiometabolic effects of adiposity are stronger and begin earlier in the life course among males compared with females until mid life, particularly for key atherogenic lipids. Adolescent and young adult males may therefore be high priority targets for obesity prevention efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UK Medical Research Council (MRC) and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and LMOK will serve as guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). This research was specifically funded by Wellcome (Grant ref: 084632/Z/08/Z, 076467/Z/05/Z, WT092830/Z/10/Z and 092731), the MRC (Grant ref: MC_UU_12013/1) and the National Institute for Health Research (NIHR) (Grant ref: NF-SI-0611-10196). LMOK is supported by a Health Research Board (HRB) of Ireland Emerging Investigator Award (EIA-FA-2019-007 SCaRLeT). JAB is supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). KON is supported by a Health Research Board (HRB) of Ireland Emerging Investigator Award (EIA-FA-2019-007 SCaRLeT). ML is funded by an MRC GW4 studentship (MR/R502340/1). SAEP is supported by a UK Medical Research Council Skills Development Fellowship (MR/P014550/1). GDS works in a unit that receives funds from the UK Medical Research Council (grant MC_UU_00011/3, MC_UU_00011/6). These funding sources had no role in the design and conduct of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the ALSPAC Law and Ethics and Local Research Ethics Committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon submission and approval of a proposal to the ALSPAC Executive. Further information is available at http://www.bristol.ac.uk/alspac/researchers/our-data/.